Mar 28, 2025 | 50 states and territories | Alaska | Apotex | Arizona | artificially inflate and manipulate prices | AUROBINDO PHARMA USA INC. | California | Colorado | Connecticut | Conspiracy to Inflate Drug Prices | DCA | Delaware | Division of Consumer Affairs | Division of Law | Florida | generic drug manufacturer | generic prescription drugs | Georgia | Heritage Pharmaceuticals | Idaho | Illinois | Inc. | Indiana | Iowa | Kansas | Kentucky | Limit Competition | Louisiana | Maine | Maryland | Massachusetts | Michigan | Minnesota | Mississippi | Missouri | Montana | Nebraska | Nevada | New Hampshire | New Jersey | New Mexico | New York | North Carolina | North Dakota | Northern Mariana Islands | Ohio | Oklahoma | Oregon | Pennsylvania | preliminary approval for a settlement | Puerto Rico | reduce competition | Rhode Island | SANDOZ | Settlement | South Carolina | South Dakota | Tennessee | TEVA PHARMACEUTICALS USA INC. | the District of Columbia | U.S. District Court for the District of Connecticut | U.S. Virgin Islands | unreasonably restrain trade | Utah | Vermont | Virginia | Washington | West Virginia | widespread long-running conspiracies | Wisconsin | Wyoming. | Division of Consumer Affairs | Division of Law | Press Release | Protecting New Jersey Consumers | Protecting New Jersey in Court
Attorney General Matthew J. Platkin is urging consumers to check their eligibility for compensation for certain generic drug purchases as New Jersey joins 50 states and territories in seeking preliminary approval for a $39.1 million settlement with generic drug manufacturer Apotex over conspiracy to inflate prices and limit competition.
Feb 28, 2025 | Bureau of Securities | Consumer Protection Enforcement Highlights | consumer protection initiatives | DCA | Division of Consumer Affairs | Division of Law | high volume of consumer complaints | impede consumers’ ability to make informed purchasing decisions | Office of Consumer Protection | Office of Weights and Measures | targeted crackdowns | taskforce sweeps | undercover investigations | unfair and deceptive conduct | unlawful business practices | unscrupulous investment schemes | Consumer Protection | Division of Consumer Affairs | Division of Law | Press Release | Protecting New Jersey Consumers
Attorney General Matthew J. Platkin and the Division of Consumer Affairs (“Division”) announced highlights of various consumer protection initiatives carried out by the Division in 2024, including those aimed at putting a stop to unlawful business practices that impede consumers’ ability to make informed purchasing decisions, shutting down unscrupulous investment schemes putting New Jersey investors at risk, and halting unfair and deceptive conduct in industries that historically generate a high volume of consumer complaints in New Jersey each year.
Dec 19, 2024 | Bergen County | DCA | Division of Consumer Affairs | Enforcement Bureau | exploitation of trust | healthcare practitioner | in appropriate remarks | Investigations | License Revoked | patient | Physical Therapist | rules of professional conduct | Sexual Relations | State Board of Physical Therapy Examiners | Consumer Protection | Division of Consumer Affairs | Division of Law | Press Release
Attorney General Matthew J. Platkin and the Division of Consumer Affairs announced that the State Board of Physical Therapy Examiners (“Board”) has revoked the license of a North Jersey physical therapist who admitted to engaging in sexual relations with one patient and allegedly made inappropriate remarks to another.
Oct 28, 2024 | 51 professional and occupational boards | 60000 registered businesses | 750000 licensed professionals | Bureau of Securities | Cari Fais | Charities Section | Cybersecurity | data privacy | DCA | Division of Consumer Affairs | First Latina Director | Legalized Games of Chance | Office of Consumer Protection | Office of Weights and Measures | Regulated Business Section | Senate confirmation | technology accountability | Consumer Protection | Division of Consumer Affairs | Press Release | Protecting New Jersey Consumers | Protecting New Jersey in Court
Attorney General Matthew J. Platkin today announced the confirmation of Cari Fais as the Director of the Division of Consumer Affairs (“Division”).
Oct 16, 2024 | Adopted New Rules | DCA | Division of Consumer Affairs | Drug Affordability Council | drug supply chain | emerging trends in drug pricing | How and Why Prices Are Increased | insurance carriers | manufacturers | pharmacy benefits managers | pharmacy services administrative organizations | Prescription Drug Prices | Promoting Greater Transparency in Prescription Drug Pricing | regulatory policies | Wholesalers | Consumer Protection | Division of Consumer Affairs | Press Release | Proposed Rules | Protecting New Jersey in Court
Advancing the Murphy Administration’s efforts to rein in the high cost of prescription drugs in New Jersey, Attorney General Matthew J. Platkin and the Division of Consumer Affairs (“Division”) announced specially adopted new rules promoting greater transparency in prescription drug pricing.
